Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALACTIC-1 phase 2b trial of inhaled GB0139 in idiopathic pulmonary fibrosis
MOH_2019-04-15_006013Phase 2Active, not recruiting
- Sponsor
- Galecto, Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GB0139 once daily inhalation with Placebo once daily inhalation (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Mar 2019; status: active, not recruiting.
02
Drugs
GB0139
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2019-04-15_006013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-15_006013.